focus -WSS

focus

author：Wikipedia 2025-08-24 09:38:02 - browse：54

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Steward Health Care files for bankruptcy

WSS

What nurses really want: sufficient staffing for patient care

Elevance, private equity launch primary care company

Eli Lilly, Pfizer, and others want in on the online prescription market

First recipient of genetically engineered pig kidney has died

Dewpoint Therapeutics lays off staff after losing partnerships

Telehealth startups turn to complex chronic diseases

focus

focus

focus

Cancer drug shortages should be causing more outrage

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Drug repurposing or repositioning? The language matters

H5N1 communication has been strictly for the birds

The high cost of giving birth even with insurance

H5N1 communication has been strictly for the birds

Affirmative action in medical school literally saved lives

Use wet bulb globe temperature, not heat index, to protect workers

Medicare details structure of new drug price negotiation program

My yearlong odyssey to get my son’s ADHD medication covered

Wikipedia

How to improve immunocompromised access to mAb treatments

Medicare Advantage today, explained in one chart

Think you might have Covid

Think you might have Covid

Why doctors need education on FDA device approval process

Steward Health Care files for bankruptcy

knowledge

hotspot

knowledge

leisure time